Jeffrey E Rubnitz
Overview
Explore the profile of Jeffrey E Rubnitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
6679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Place A, Karol S, Forlenza C, Cooper T, Fraser C, Cario G, et al.
Pediatr Blood Cancer
. 2025 Mar;
:e31630.
PMID: 40062648
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis....
2.
Khanlari M, Wang W, Ni Y, Mead P, Umeda M, Westover T, et al.
Am J Surg Pathol
. 2025 Jan;
PMID: 39760616
Tandem duplications (TDs) in exons of upstream binding transcription factor (UBTF-TD) are a rare recurrent alteration in pediatric and adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)/neoplasm. Although recently...
3.
Lei S, Jia S, Takalkar S, Chang T, Ma X, Szlachta K, et al.
Leukemia
. 2024 Nov;
39(2):420-430.
PMID: 39523434
The utility of circulating tumor DNA (ctDNA) analysis has not been well-established for disease detection and monitoring of childhood cancers, especially leukemias. We developed PeCan-Seq, a deep sequencing method targeting...
4.
Badawi M, Gopalakrishnan S, Engelhardt B, Palenski T, Karol S, Rubnitz J, et al.
Clin Ther
. 2024 Oct;
46(10):759-767.
PMID: 39368878
Purpose: This work aimed to characterize the pharmacokinetics and exposure-response relationships of venetoclax in pediatric patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) to identify venetoclax doses to...
5.
Purvis K, Zhou Y, Karol S, Rubnitz J, Ribeiro R, Lee S, et al.
Blood
. 2024 Sep;
145(2):190-201.
PMID: 39316653
Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI)...
6.
Cuglievan B, Kantarjian H, Rubnitz J, Cooper T, Zwaan C, Pollard J, et al.
Leukemia
. 2024 Aug;
38(10):2073-2084.
PMID: 39179671
Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of...
7.
Marrero R, Wu H, Cao X, Parcha P, H Elsayed A, Inaba H, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4388-4396.
PMID: 39078289
Purpose: Cytarabine (also known as ara-C) has been the backbone of acute myeloid leukemia (AML) chemotherapy for more than five decades. Recent pharmacogenomics-based 10-SNP ara-C (ACS10) scores showed low ACS10...
8.
Lamba J, Marrero R, Wu H, Cao X, Parcha P, Karol S, et al.
JAMA Netw Open
. 2024 May;
7(5):e2411726.
PMID: 38753328
Importance: Disparities in outcomes exist between Black and White patients with acute myeloid leukemia (AML), with Black patients experiencing poorer prognosis compared with their White counterparts. Objective: To assess whether...
9.
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia
van Weelderen R, Harrison C, Klein K, Jiang Y, Abrahamsson J, Alonzo T, et al.
Blood Adv
. 2024 Apr;
8(12):3200-3213.
PMID: 38621200
A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1256 children...
10.
Ma J, Liu Y, Voss R, Ma J, Palagani A, Caldwell E, et al.
Leukemia
. 2024 Mar;
38(5):981-990.
PMID: 38429501
MLLT10 fusion is a rare but recurrent genetic driver in acute leukemias. To better understand the genomic landscape of PICALM::MLLT10 (PM) positive acute leukemia, we performed genomic profiling and gene...